You are here: Home: BCU CME | 2005: Case 8: Select publications
 
     
 

SELECT PUBLICATIONS

Cheung K et al. Goserelin plus anastrozole as first-line endocrine therapy for premenopausal women with oestrogen receptor (ER) positive advanced breast cancer (ABC). Proc ASCO 2005;Abstract 731.

Eedarapalli P, Jain S. Breast cancer in pregnancy. J Obstet Gynaecol 2006;26(1):1-4. Abstract

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717. Abstract

Eneman JD et al. Selecting adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 2004;18(14):1733-44. Abstract

Hilakivi-Clarke L et al. Pregnancy weight gain and premenopausal breast cancer risk. J Reprod Med 2005;50(11):811-6. Abstract

Jonat W et al. Trends in endocrine therapy and chemotherapy for early breast cancer: A focus on the premenopausal patient. J Cancer Res Clin Oncol 2006;[Epub ahead of print]. Abstract

Kaklamani VG, Gradishar WJ. Adjuvant therapy of breast cancer. Cancer Invest 2005;23(6):548-60. Abstract

Krop IE, Winer EP. Ovarian suppression for breast cancer: An effective treatment in search of a home. J Clin Oncol 2005;23(25):5869-72. Abstract

Milla-Santos A et al. Anastrozole vs tamoxifen in hormonodependent advanced breast cancer: A phase II randomized trial. Proc SABCS 2000;173. No abstract available

Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 2004;9(5):507-17. Abstract

Recchia F et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106(3):514-23. Abstract

Robert NJ et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer ≤ 3 cm. Proc ASCO 2003;Abstract 16.

Sharma et al. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer. Breast 2005;14(3):181-91. Abstract

Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract

Untch M et al. Anthracycline and trastuzumab in breast cancer treatment. Oncology (Williston Park) 2004;18(14 Suppl 14):59-64. Abstract

Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: Aromatase inhibitor or antioestrogen? Br J Cancer 2004;90(1):20-5. Abstract

 

 

  
 
 
     
 
 


 
Editor’s Note:
Common questions about breast cancer from oncologists in community practice


Case 1: An active 79-year-old woman with a 7.5-centimeter, Grade II, ER/PR-positive, HER2-negative breast cancer with lymphovascular invasion and three positive nodes (from the practice of Dr Martha A Tracy)
- Select publications

Case 2: A 41-year-old premenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma and six positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 3: A 68-year-old woman with disease progression 10 years after presenting with hormone receptor-positive diffuse metastatic disease to the bone (from the practice of Dr Ghaleb A Saab)
- Select publications

Case 4: A 91-year-old woman with dementia who was diagnosed with Stage II, ER-positive, lymph node-negative breast cancer 15 years ago and now has diffuse bone metastases (from the practice of Dr Juliann M Smith)
- Select publications

Case 5: A 41-year-old surgically postmenopausal woman with a 3.5-centimeter, ER/PR-positive, HER2-positive tumor and two positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 6: A 45-year-old premenopausal woman with a 0.7-cm, ER/PR-positive, HER2-positive tumor with 25 percent high-grade DCIS and an Oncotype DX™ recurrence score of 16 (from the practice of Dr Steven W Papish)
- Select publications

Case 7: A woman who presented in 1989 with an infiltrating lobular carcinoma and 21 positive nodes and was treated with adjuvant chemotherapy and tamoxifen and then develops metastatic disease and is treated over the next 11 years with a variety of chemotherapeutic and hormonal agents (from the practice of Dr Pamela Drullinsky)
- Select publications

Case 8: A 35-year-old woman with a 3.5-cm, ER/PR-positive, HER2-positive infiltrating ductal carcinoma and two positive sentinel lymph nodes treated on the nontrastuzumab- containing arm of the Intergroup N9831 trial (from the practice of Dr Pamela Drullinsky)
- Select publications
 
CME Information
Faculty Disclosures
Editor's Office